- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03980405
Combination of Diet and 5ASA ( 5-aminosalicylic Acid) for Ulcerative Colitis (INDUCT)
Combination Therapy With Drug and Diet for Induction of Remission in Mild to Moderate Active Pediatric Ulcerative Colitis: A Single Blinded, International Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This will be a 12 week, single blinded Randomized controlled trial (RCT) in children and adolescents with mild to moderate Ulcerative Collitis (UC) comparing 5ASA (recommended dosing 60-75 mg/kg/day; minimum 2.5 maximum 4 grams/day) with fiber restriction for 6 weeks followed by free diet (Group 1) to 5ASA with Ulcerative Collitis Diet (UCD) for 6 weeks, followed by the step down UCD for the next 6 weeks. Inclusion criteria will include children weighing >30kg, Pediatric Ulcerative Collitis Activity index (PUCAI) 10-45, no treatment with 5ASA (treatment naïve or treated with thiopurines for example) or currently treatment with 5ASA but <2 grams/day, ages 10-19 years, with disease extent E2-E4 by the Paris Classification. Patients on thiopurines may continue existing dose if dose is stable for at least 8 weeks.
Exclusion criteria are Patients with acute severe colitis (ASC) in the previous year, requiring oral or intravenous steroids in the previous 3 months, or patients treated with Anti- Tumor necrosis factor alfa (TNFa) regimens. Importantly, there is no placebo arm and both groups will be treated with the same currently recommended drug at currently recommended doses; the only difference between groups being their diets.
The primary endpoint will be remission defined as PUCAI<10 at week 6; Secondary endpoints will be response defined as a drop in PUCAI of 10 or remission at week 6, sustained steroid free remission week 12 and improvement in mucosal healing by Ulcerative Colitis Endoscopic Index of Severity (UCEIS) at week 12 as well as safety and tolerance. Intolerance will be defined as patients stopping the diet because of refusal to continue diet. Patients will be seen at weeks 0, 3, 6, and 12. PUCAI will be assessed at every visit; fecal calprotectin will be assessed at baseline, week 6 and 12. Sigmoidoscopy to assess mucosal healing will be performed at week 12 in patients who had a baseline colonoscopy or sigmoidoscopy. Sigmoidoscopies to evaluate healing will be voluntary and patients will not be excluded if they do not consent to have a follow up sigmoidoscopy.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Holon, Israel, 5822012
- Wolfson MC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Informed consent
- Established diagnosis of UC by the Paris classification and Revised Porto Criteria.
- Age: 10 - 19 years (inclusive)
- Mild to moderate active disease, 10 ≤ PUCAI ≤45
- Extent E2-E4 by the Paris classification
- Weight >30 kg (ensures that patients who received 5ASA ≤2 grams are eligible)
- Stable medication (IMM/ 5ASA) use or no change in medication use for the past 6 weeks. Patients who have received topical 5ASA therapy for <10 days and are active may be included if topical therapy is stopped at enrolment.
- Patients not receiving 5ASA or using 5ASA<50mg/kg/day
Exclusion Criteria:
- Any proven current infection such as positive stool culture, parasite or C. difficile.
- Steroids (oral or intravenous) use in the past 3 months.
- Patients who continue topical 5ASA or steroids after enrolment
- Use of biologics in present or in past 6 months
- Use of antibiotics for more than one week in the past 60 days
- PUCAI >45
- Acute severe UC in the previous 12 months.
- Current extra intestinal manifestation of UC.
- Primary Sclerosing Cholangitis (PSC) or Liver disease
- Pregnancy.
- Vegans or patients unwilling or unable to consume eggs
- Inflammatory Bowel Disease (IBD) unclassified
Exclusion criteria Comments:
- Stool culture, parasite or C. difficile will only be measured if the patient has diarrhea.
- Patients who have received treatment enemas for 3 weeks or less then 3 days and are active, can be included but must stop the enemas on the day of enrolment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1
Control Diet 6 weeks of Oral 5ASA (standard recommended dosing 60-75 mg/kg/day; minimum 2.5, maximum 4 grams/day)+ Low residue diet and 6 more weeks of Oral 5ASA+ Free diet
|
Oral 5ASA+ Low Residue Diet for 6 weeks and Oral 5ASA+ Free Diet for 6 more weeks
|
Experimental: Group 2
6 weeks of Oral 5ASA (standard recommended dosing 60-75 mg/kg/day; minimum 2.5, maximum 4 grams/day)+ UC diet and 6 more weeks of Oral 5ASA+ UC diet stage 2
|
Oral 5ASA+ UC Diet for 6 weeks and Oral 5ASA+ UC Diet Stage 2 for 6 more weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PUCAI< 10 at week 6
Time Frame: 6 weeks
|
Remission defined as PUCAI<10 at week 6
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
A drop of PUCAI at least 10 points or remission
Time Frame: 6 weeks
|
Response defined as a drop of PUCAI at least 10 points or remission (intention to treat) week 6 .
|
6 weeks
|
Mean/median change in Calprotectin at week 6
Time Frame: 6 weeks
|
Mean/median change in Calprotectin at week 6
|
6 weeks
|
Sustained remission week 12
Time Frame: 12 weeks
|
Sustained steroid & biologic free remission week 12
|
12 weeks
|
Need for topical therapy by week 12
Time Frame: 12 weeks
|
Need for topical therapy by week 12
|
12 weeks
|
Change in UCEIS at week 12 ( optional)
Time Frame: 12 weeks
|
Change in UCEIS at week 12 ( optional)
|
12 weeks
|
Tolerance to diet
Time Frame: 12 weeks
|
Tolerance to diet defined by withdrawal from the study because of difficulties with the diet.
|
12 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Arie Levine, Prof, Wolfson Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0001-19-WOMC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ulcerative Colitis
-
Ferring PharmaceuticalsCompletedActive Ulcerative Colitis | Remission of Ulcerative ColitisCanada
-
Palatin Technologies, IncRecruitingUlcerative Colitis | Ulcerative Colitis Flare | Ulcerative Colitis Acute | UlcerativeUnited States
-
Theravance BiopharmaCompletedUlcerative Colitis, Active Severe | Ulcerative Colitis, Active ModerateUnited States, Georgia, Moldova, Republic of, Romania
-
Rise Therapeutics LLCUniversity of Colorado, Denver; Mayo ClinicRecruitingUlcerative Colitis | Ulcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic | Ulcerative Colitis Chronic MildUnited States
-
Assistance Publique - Hôpitaux de ParisMRSU 938 - Research Center of Saint AntoineNot yet recruitingPediatric Ulcerative Colitis in RemissionFrance
-
Protagonist Therapeutics, Inc.CompletedUlcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic SevereUnited States, Austria, Bulgaria, Canada, Georgia, Germany, Hungary, Italy, Korea, Republic of, Poland, Russian Federation, Serbia, Ukraine
-
Theravance BiopharmaCompletedActive Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy SubjectsUnited States
-
Altheus Therapeutics, Inc.UnknownUlcerative Colitis | Left-sided Ulcerative Colitis | Distal Ulcerative ColitisUnited States
-
Groupe d'Etude Therapeutique des Affections Inflammatoires...CompletedIntensive Treatment to Reach the Target With Golimumab in ulcErative coliTis - In-TARGET (In-TARGET)ULCERATIVE COLITISFrance, Belgium
-
Academisch Medisch Centrum - Universiteit van Amsterdam...University Medical Center Groningen; UMC UtrechtRecruitingUlcerative Colitis | Ulcerative Colitis Flare | Ulcerative Colitis AcuteNetherlands
Clinical Trials on Group 1- Control Diet
-
Emory UniversityCompleted
-
Arkansas Children's Hospital Research InstituteRecruiting
-
University of RoehamptonUniversitat Autonoma de Barcelona; University College CorkRecruiting
-
University of ChileFondo Nacional de Desarrollo Científico y Tecnológico, ChileTerminatedMetabolic SyndromeChile
-
Clinica Alemana de SantiagoComisión Nacional de Investigación Científica y TecnológicaCompletedStroke, Ischemic | Stroke, AcuteChile
-
Physicians Committee for Responsible MedicineMetropolitan Police Department of Washington, D.C.SuspendedDiabetes Mellitus, Type 2 | Overweight | Blood PressureUnited States
-
Mahitab Mohammed Yosri IbrahimCompletedPolycystic Ovary Syndrome
-
Washington University School of MedicineCompletedHypertension | Overweight | Glucose Intolerance | Hypercholesterolemia | Pre-hypertensionUnited States
-
University of AlexandriaCompleted
-
University of PalermoAurelio SeiditaRecruitingSjogren's Syndrome | Non-celiac Gluten SensitivityItaly